Skip to content

Investigation of Immune Disorders and Deficiencies

Investigation of Molecular, Genetic and Cellular Mechanisms of Human Immune Disorders and Deficiencies

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01981785
Enrollment
343
Registered
2013-11-13
Start date
2012-12-31
Completion date
2018-12-31
Last updated
2017-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Diseases, Common Variable Immune Deficiencies, Hypogammaglobulinemia, Inflammatory Diseases, Primary Immune Deficiencies

Keywords

Primary immune deficiencies, Autoimmune diseases, Inflammatory diseases, Common variable immune deficiencies, Primary Immunodeficiencies, Immunoglobulin, IgG, IVIG, Recurrent Infections

Brief summary

The immune system is an intricate system comprised of specialized cells, proteins, tissues and organs. Proper functioning is critical to the body's ability to defend itself against harmful pathogens. Immunological disorders and deficiencies are defects in the immune system that lead to abnormal immune responses. Abnormal immune responses could be derived from immune deficiencies, dysregulations or hypersensitivities. The overall goal of this research study is to identify the mechanisms of primary immune deficiencies and immune disorders at the genetic, cellular and molecular level, using novel analytic techniques to be performed on immune cells derived from blood samples. The knowledge gained from the aims of this study could lead to better diagnostics and identify novel targets for therapeutic interventions.

Detailed description

Primary immunodeficiency diseases (PID) represent a class of disorders in which there is an instrinsic defect in the human immune system. The PID could be caused by defects or perturbations in either the innate or adaptive immune cells, such as B cell defects which result in lack of antibodies. Research in this topic remains a difficult feat due factors such as genetic heterogeneity and the gene-environment interface. Limitations of standard of care testing leads to many patients with immunological problems to be undiagnosed. In addition to the variety of primary immune deficiencies, there are large number of immune system disorders due to various perturbations in the immunological components that cause diseases with much greater prevalence such as autoimmune diseases, lymphoproliferative diseases, chronic inflammation and certain cancers. The causes of these immune disorders are typically more complex than PID but there are also many overlaps in immune hyper-activation and deficiency.

Interventions

None listed

Sponsors

O & O Alpan LLC
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Days to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Subject is greater than or equal to 1 day of age and less than or equal to 100years of age * Signed Informed Consent/Assent * Subject is able and willing to comply with study protocol requirements * From clinical or blood laboratory findings subject has evidence of immune abnormalities (or no immune abnormalities in the case of controls) or immune-mediated disease.

Exclusion criteria

* Risk factors for donating blood (such as anemia or blood clotting disorders)

Design outcomes

Primary

MeasureTime frameDescription
Genetic variants10 yearsTo elucidate genetic variants associated with various previously identified immune disorders to include but not limited to immune dysregulations, hypersensitivities, inflammatory conditions and deficiencies.

Secondary

MeasureTime frameDescription
Pathogenesis10 yearsTo further elucidate pathogenesis of previously discovered immune disorders or subjects with suspected allergic/immunological disorders using cell surface and intracellular staining techniques using flow cytometry.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026